A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Gram Negative Infections
Interventions
DRUG

Meropenem plus vaborbactam

Meropenem plus vaborbactam fixed dose combination adjusted by body weight up to 2g/2g

Trial Locations (20)

Unknown

RECRUITING

Fakultni nemocnice Ostrava, Ostrava

RECRUITING

Faculty Hospital Kralovske Vinohrady, Paediatric Clinic, Prague

RECRUITING

Hôpital mère-enfant - CHU de Nantes, Nantes

RECRUITING

Nice University Hospital (CHU de Nice), Nice

RECRUITING

Hospital Armand Trousseau Clinical Research Site, Paris

RECRUITING

Hôpital Robert Debré, Paris

RECRUITING

CHRU de Tours Hôpital Clocheville Clinical Research Site, Tours

RECRUITING

Policlinico di Bari, Bari

RECRUITING

Giannina Gaslini Institute, Genoa

RECRUITING

Azienda Ospedaliero-Universitaria di Parma, Parma

RECRUITING

Ospedale Pediatrico Bambino Gesù, Rome

RECRUITING

Ospedale Regina Margherita, Torino

RECRUITING

Insytut Centrum Zdrowia Matki Polki / Polish Mother´s Memorial Hospital Research Institute (ICZMP), Lodz

RECRUITING

Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy, Warsaw

RECRUITING

Hospital Sant Joan de Deu, Barcelona

RECRUITING

Hospital Universitario Puerta del Mar, Cadiz

RECRUITING

Hospital Dr Josep Trueta, Girona

RECRUITING

Hospital General Universitario Gregorio Marañón, Madrid

RECRUITING

Hospital Regional Universitario de Málaga, Málaga

RECRUITING

Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Menarini Group

INDUSTRY

NCT06828848 - A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections | Biotech Hunter | Biotech Hunter